PLS Pharma | Menu

HPRA Drug Safety on Valproate (Epilim) and Domperidone

The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:

Valproate (Epilim) and Developmental Disorders: Update on ongoing EU review

Domperidone-containing medicines: reminder of the risk of cardiac adverse reactions-restricted indication, contraindications and reduced dose and duration of use

New CPD e-learning module on reporting suspected adverse drug reactions

Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter.

Download:      hpra-drug-safety-newsletter-edition-81.pdf     242 KB